Lords Mark Industries Limited approved an enhancement of its Board's borrowing powers to an overall limit of ₹1,000 crore during its 46th Annual General Meeting held on September 30, 2026. The shareholder mandate, sought under Section 180(1)(c) of the Companies Act, 2013, significantly expands the company's financial flexibility for future operations and capital requirements.

The virtual meeting, conducted via Video Conferencing/Other Audio-Visual Means, also authorized the Board to provide loans, guarantees, or securities up to ₹50 crore under Section 185, and to make investments and loans beyond prescribed limits up to ₹50 crore under Section 186. These approvals signal a strategic shift towards leveraging balance sheet capacity, although specific utilization plans were not detailed in the proceedings.

Leadership and governance updates

Shareholders reappointed Manav Kishore Teli as Executive Director following his retirement by rotation. The meeting also saw the appointment of four new Independent Directors for five-year terms: Shweta Dilip Mehta, Govind Singh Bhati, Vinod Tiwari, and Pooja Vijay Gohil. This refreshment of the board composition aims to strengthen oversight mechanisms.

Auditor appointments

M/s. Sanjeev S. Gupta & Associates were appointed as Statutory Auditors for a five-year term from FY27 to FY31. CS Geeta Serwani was appointed as Secretarial Auditor for FY27 to FY31. Additionally, shareholders ratified the remuneration payable to M/s. Raj Kaushik & Associates as Cost Auditors for FY27.

Key resolutions passed

The adoption of audited financial statements for FY26 was completed without dissent. Voting results are expected to be announced within 48 hours in compliance with SEBI Listing Regulations.

Lords Mark Industries Limited secured Medicines & Healthcare products Regulatory Agency (MHRA) registration in the UK for its AI-powered haemodialysis system. Exports to the UK and allied markets are scheduled to commence in early January 2027.

The registration covers Renalyx Health Systems Pvt. Ltd. as the manufacturer, with the haemodialysis system registered under GMDN Code 58131 for institutional and home use. The company positions this as India's first and the world's first AI-powered dialysis ecosystem to achieve this regulatory milestone at this pace, aligning with the India-UK Free Trade Agreement (FTA).

AI-powered renal care ecosystem

Unlike conventional models where machines operate as isolated equipment, Lords Mark's ecosystem integrates the Renalyx machine with RenalOS, an AI-powered clinical intelligence platform. The system enables real-time monitoring of treatment parameters, predictive alerts, and data-driven decision support during dialysis sessions. RenalOS supports the identification of early warning signals, while connected technology extends monitoring beyond the dialysis centre.

The company plans a dual business model: supplying Renalyx systems to healthcare providers and establishing its own dialysis centres. This approach allows participation across the renal-care value chain, from medical technology and AI-driven clinical intelligence to infrastructure and patient care delivery.

Breast cancer screening progress

Concurrently, Lords Mark advanced its AI-powered breast cancer screening technology to final clinical trials across the USA, Great Britain, and Europe. The company targets commercial placement of this radiation-free wearable device by April 2027.

The Technical Committee approved the final trial stage following the completion of clinical trials in India. These initial trials demonstrated accurate identification of cases, with data contributing to ongoing regulatory evaluation. Phase 2 trials, aiming for 98% accuracy in detecting cancer at the cell level, will commence in January 2027.

Regulatory and strategic outlook

For the breast cancer device, Lords Mark is progressing through regulatory evaluation in India, with CDSCO approval in process. The company is also addressing requirements for European conformity and US FDA pathways. Key regulatory milestones are targeted for completion before March 2027, subject to clinical outcomes and independent verification. Representations have been made to authorities for inclusion in national breast cancer screening programmes and insurance coverage consideration through IRDAI.

The development of both technologies involves collaboration with the Centre for Materials for Electronic Technology (C-MET), combining R&D expertise with manufacturing capabilities. Sachidanand Upadhyay, Managing Director, stated that these milestones validate the vision of building world-class medical technology in India for global markets.

What the Numbers Show

The simultaneous advancement of two distinct medical devices highlights a diversification strategy within Lords Mark's healthcare segment. While the breast cancer screening market is projected to nearly double from $5.9 billion in 2025 to $11.4 billion by 2033, the dialysis ecosystem targets a different operational model. The dialysis entry leverages an existing FTA framework for immediate export capability (January 2027), whereas the breast cancer device relies on longer-term regulatory approvals (April 2027 target). This suggests a phased revenue recognition strategy, with dialysis potentially contributing earlier via exports and centre operations, while the screening device awaits broader market access approvals.